Global Pediatric Growth Hormone Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Pediatric Growth Hormone Market Research Report 2024
Growth hormones deficiency is a rare condition but it mainly affects the children. The recombinant form of a growth hormone called somatotropin is generally prescribed to treat pediatric patients with growth hormone deficiency. Somatotropin or growth hormone injections are prescribed for pediatric patients with turner syndrome, short stature, Prader-Willi syndrome, Noonan syndrome and other disorders.
According to Mr Accuracy reports new survey, global Pediatric Growth Hormone market is projected to reach US$ 4690 million in 2029, increasing from US$ 3300 million in 2022, with the CAGR of 5.2% during the period of 2024 to 2029.
The global pediatric growth hormone market refers to the market for medications and therapies used to treat growth hormone deficiency (GHD) and related disorders in children. Growth hormone is an important hormone produced by the pituitary gland that plays a crucial role in regulating growth, development, and metabolism.
Pediatric growth hormone deficiency can occur due to various factors, including genetic conditions, congenital anomalies, brain injuries, and certain medical treatments. Treatment with growth hormone therapy aims to stimulate growth and development in children who have insufficient or inadequate production of growth hormone.
The global market for pediatric growth hormone is primarily driven by factors such as the increasing prevalence of growth hormone deficiency, rising awareness about the benefits of growth hormone therapy, advances in treatment options, and improving healthcare infrastructure.
Growth hormone therapy for children with growth hormone deficiency involves the subcutaneous administration of synthetic growth hormone on a daily basis. The therapy is typically initiated during childhood and continued until the patient reaches adult height or the maximum growth potential is achieved.
Geographically, North America and Europe hold a significant share in the global pediatric growth hormone market due to the well-established healthcare systems, high awareness levels, and the presence of key market players. The Asia Pacific region is also expected to witness significant growth due to the increasing prevalence of growth hormone deficiency and improving healthcare infrastructure.
Key pharmaceutical companies involved in the production and distribution of pediatric growth hormone products include Novo Nordisk, Pfizer, Eli Lilly and Company, Merck & Co., and Ferring Pharmaceuticals, among others. These companies are focused on developing advanced growth hormone formulations, conducting clinical trials, and expanding their product portfolios to address the specific needs of pediatric patients.
It’s important to note that the pediatric growth hormone market is regulated, and treatment decisions are made based on the diagnosis and guidance of healthcare professionals specializing in pediatric endocrinology. Proper assessment, diagnosis, and monitoring of the child’s growth and hormone levels are essential for safe and effective treatment.
In summary, the global pediatric growth hormone market is driven by factors such as the increasing prevalence of growth hormone deficiency, advances in treatment options, and improving healthcare infrastructure. The market is expected to witness steady growth as awareness about growth hormone therapy increases and healthcare providers continue to diagnose and treat pediatric patients with growth hormone deficiency.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Pediatric Growth Hormone market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Merck KGaA
Novo Nordisk A/S
Ferring B.V
Genentech, Inc.
Pfizer Inc.
Eli Lilly & Company
Novartis AG
BioPartners GmbH
Ipsen Biopharmaceuticals
Teva Pharmaceuticals
Anhui Anke Biotechnology (Group) Co., Ltd.
LG Chem
GeneScience Pharmaceuticals Co., Ltd.
Ascendis Pharma A/S
Changchun High & New Tech Industry Inc
Segment by Type
Growth Hormone Deficiency
Turner Syndrome
Prader-Willi Syndrome
Noonan Syndrome
Others
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Pediatric Growth Hormone report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
According to Mr Accuracy reports new survey, global Pediatric Growth Hormone market is projected to reach US$ 4690 million in 2029, increasing from US$ 3300 million in 2022, with the CAGR of 5.2% during the period of 2024 to 2029.
The global pediatric growth hormone market refers to the market for medications and therapies used to treat growth hormone deficiency (GHD) and related disorders in children. Growth hormone is an important hormone produced by the pituitary gland that plays a crucial role in regulating growth, development, and metabolism.
Pediatric growth hormone deficiency can occur due to various factors, including genetic conditions, congenital anomalies, brain injuries, and certain medical treatments. Treatment with growth hormone therapy aims to stimulate growth and development in children who have insufficient or inadequate production of growth hormone.
The global market for pediatric growth hormone is primarily driven by factors such as the increasing prevalence of growth hormone deficiency, rising awareness about the benefits of growth hormone therapy, advances in treatment options, and improving healthcare infrastructure.
Growth hormone therapy for children with growth hormone deficiency involves the subcutaneous administration of synthetic growth hormone on a daily basis. The therapy is typically initiated during childhood and continued until the patient reaches adult height or the maximum growth potential is achieved.
Geographically, North America and Europe hold a significant share in the global pediatric growth hormone market due to the well-established healthcare systems, high awareness levels, and the presence of key market players. The Asia Pacific region is also expected to witness significant growth due to the increasing prevalence of growth hormone deficiency and improving healthcare infrastructure.
Key pharmaceutical companies involved in the production and distribution of pediatric growth hormone products include Novo Nordisk, Pfizer, Eli Lilly and Company, Merck & Co., and Ferring Pharmaceuticals, among others. These companies are focused on developing advanced growth hormone formulations, conducting clinical trials, and expanding their product portfolios to address the specific needs of pediatric patients.
It’s important to note that the pediatric growth hormone market is regulated, and treatment decisions are made based on the diagnosis and guidance of healthcare professionals specializing in pediatric endocrinology. Proper assessment, diagnosis, and monitoring of the child’s growth and hormone levels are essential for safe and effective treatment.
In summary, the global pediatric growth hormone market is driven by factors such as the increasing prevalence of growth hormone deficiency, advances in treatment options, and improving healthcare infrastructure. The market is expected to witness steady growth as awareness about growth hormone therapy increases and healthcare providers continue to diagnose and treat pediatric patients with growth hormone deficiency.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Pediatric Growth Hormone market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Merck KGaA
Novo Nordisk A/S
Ferring B.V
Genentech, Inc.
Pfizer Inc.
Eli Lilly & Company
Novartis AG
BioPartners GmbH
Ipsen Biopharmaceuticals
Teva Pharmaceuticals
Anhui Anke Biotechnology (Group) Co., Ltd.
LG Chem
GeneScience Pharmaceuticals Co., Ltd.
Ascendis Pharma A/S
Changchun High & New Tech Industry Inc
Segment by Type
Growth Hormone Deficiency
Turner Syndrome
Prader-Willi Syndrome
Noonan Syndrome
Others
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Pediatric Growth Hormone report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices